Issues related to patent policy and reform, including to address patent thickets (HR 6986, S. 3583) and Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220, HR 4370), and Patent Eligibility Restoration Act of 2023 (S. 2140)
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429)
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition;
issues related to drug shortages;
DRUG Act (HR 6283, S. 1542).
Duration: February 15, 2022
to
present
General Issues: Copyright/Patent/Trademark , Medicare/Medicaid , Health Issues , Pharmacy
Spending: about $350,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2022: U.S. Senate, House of Representatives, Commerce - Dept of (DOC), Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), White House Office
Related Foreign Entities:
Fresenius Kabi SwissBioSim GmbH (CH - 1262 Eysins, SUI); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Ashley Davis Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the President
Craig Kalkut Staff Director/Chief Counsel, Senate Judiciary Committee; Analyst, Senate Budget Committee; Counsel, Legislative Assistant, Special Assistant to Chief Staff, Senator Kent Conrad
Malloy McDaniel Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
Kristi Remington Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform Committee
Shimon Stein Senior Policy Advisor, House Majority Leader Eric Cantor; Program Manager, US Department of Justice; Legislative Correspondent, Senator John Ashcroft; Paid Intern, Represenative Robert Aderholt
Christopher Buki Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $50,000. The report was filed on April 20.
Original Filing: 301567957.xml
Lobbying Issues
Issues related to patent policy and reform, including to address patent thickets (HR 6986, S. 3583) and Promoting and Respecting Economically Vital American Innovation Leadership Act (S. 2220, HR 4370), and Patent Eligibility Restoration Act of 2023 (S. 2140)
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429)
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition;
issues related to drug shortages;
DRUG Act (HR 6283, S. 1542).
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on Jan. 15.
Original Filing: 301524824.xml
Lobbying Issues
Issues related to patent policy and reform, including terminal disclaimers;
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429)
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition;
issues related to drug shortages;
DRUG Act (HR 6283, S. 1542).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515427.xml
Lobbying Issues
Issues related to patent policy and reform, including terminal disclaimers;
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79) and Medication Affordability and Patent Integrity Act (S. 2780, HR 5429)
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition;
issues related to drug shortages.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301488239.xml
Lobbying Issues
Issues related to patent policy and reform, including terminal disclaimers;
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79);
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition;
issues related to drug shortages.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on April 19, 2023.
Original Filing: 301459489.xml
Lobbying Issues
Issues related to patent policy and reform, including terminal disclaimers;
FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79);
Prescription Pricing for the People Act of 2023 (S.113);
Preserve Access to Affordable Generics and Biosimilars Act (S.142);
Affordable Prescriptions for Patients Act of 2023 (S.150).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to competition.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301443557.xml
Lobbying Issues
Issues related to patent policy and reform, including Restoring the America Invents Act, S. 2891 and the Patent Trial and Appeal Board Reform Act of 2022, S.4417.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to Electronic Labeling;
Issues related to FDA User Fee legislation;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to competition.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on Oct. 19, 2022.
Original Filing: 301410626.xml
Lobbying Issues
Issues related to patent policy and reform, including Restoring the America Invents Act, S. 2891 and the Patent Trial and Appeal Board Reform Act of 2022, S.4417.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing;
issues related to Biosimilars;
issues related to Electronic Labeling;
Issues related to FDA User Fee legislation;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to competition.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301393843.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent policy and reform, including Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, West Front Strategies LLC lobbied for Fresenius Kabi USA LLC , earning $20,000. The report was filed on April 20, 2022.
Original Filing: 301372408.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent reform, including Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
West Front Strategies LLC filed a lobbying registration on March 30, 2022 to represent Fresenius Kabi USA LLC, effective Feb. 15, 2022.
Original Filing: 301343174.xml
Issue(s) they said they’d lobby about: Issues related to drug pricing legislation, biosimilars, patent reform, rebate reform, electronic labeling,and FDA Foreign Inspection backlog. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...